Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mentor Hyalite dermal filler

This article was originally published in The Gray Sheet

Executive Summary

Pivotal study commences of the non-animal stabilized hyaluronic acid dermal filler, comparing the device with Medicis' approved Restylane HA filler. Six-month data from the 12-month study will be submitted in support of a planned PMA application for facial wrinkle correction and lip augmentation. The latter application would be a first for an HA filler. Hyalite includes lidocaine anesthetic to alleviate pain during injection. Mentor acquired the device via its August 2003 acquisition of Vitrolife AB subsidiary A-Life (1"The Gray Sheet" Sept. 8, 2003, p. 19)...

You may also be interested in...

Medicis Lab-Derived Dermal Filler On Track For Year-End Approval – Exec

Medicis will hire a 30-40 rep sales force for Q-Med's Restylane non-animal stabilized hyaluronic acid (NASHA)-based surgical wrinkle treatment in time for the product's launch, anticipated by 2004

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says

As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts